American Association for Cancer Research
crc-22-0037-s03.pdf (1.91 MB)

Supplementary Figures 1-7 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Download (1.91 MB)
journal contribution
posted on 2023-04-04, 01:22 authored by Stefano Marastoni, Ainhoa Madariaga, Aleksandra Pesic, Sree Narayanan Nair, Zhu Juan Li, Zvi Shalev, Troy Ketela, Ilaria Colombo, Victoria Mandilaras, Michael Cabanero, Jeff P. Bruce, Xuan Li, Swati Garg, Lisa Wang, Eric X. Chen, Sarbjot Gill, Neesha C. Dhani, Wenjiang Zhang, Melania Pintilie, Valerie Bowering, Marianne Koritzinsky, Robert Rottapel, Bradly G. Wouters, Amit M. Oza, Anthony M. Joshua, Stephanie Lheureux

Supplementary Figure 1: Itra dose response in ovarian cancer cell lines. - Supplementary Figure 2: Analysis on ovarian cancer cell lines used in the Itra-sensitizing CRISPR screen (OVCAR5 and TOV1946). - Supplementary Figure 3: c18orf8 and VPS54 Knockout effects on the TOV1946 cell line. - Supplementary Figure 4: Itra+CQ dose responses. - Supplementary Figure 5: 5/10 uM CQ response and apoptosis assay results. - Supplementary Figure 6: Itra+CQ dose response in c18orf8 and VPS54 knockout cells and calculation of synergy scores. - Supplementary Figure 7: Intratumoural Itra/CQ detection and Ki-67 analysis in patient samples.


Government of Ontario (Ontario Government)



The combination of the antifungal drug itraconazole with antimalarial drug hydroxychloroquine leads to a cytotoxic lysosomal dysfunction, supporting the rational for further research on lysosomal targeting in ovarian cancer.